Tvardi Therapeutics (FRA:69C) Ending Cash Position: €17.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:69C Tvardi Therapeutics Inc FRA:69C
19 GF Score
Price €1.20
! 1 Warning Sign
View Full Analysis

What is Tvardi Therapeutics Ending Cash Position?

Tvardi Therapeutics FRA:69C -22.08% 19 Ending Cash Position is €17.17 Mil as of Mar. 2026. GuruFocus rates FRA:69C with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Tvardi Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was €17.17 Mil.

Tvardi Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 (€18.25 Mil) to Dec. 2025 (€17.71 Mil) and declined from Dec. 2025 (€17.71 Mil) to Mar. 2026 (€17.17 Mil).

Tvardi Therapeutics's annual Ending Cash Position increased from Dec. 2023 (€21.02 Mil) to Dec. 2024 (€30.19 Mil) but then declined from Dec. 2024 (€30.19 Mil) to Dec. 2025 (€17.71 Mil).

Tvardi Therapeutics Ending Cash Position Related Terms

Tvardi Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Ending Cash Position Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
20.29 21.02 30.19 17.71

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 10.58 17.90 18.25 17.71 17.17
FRA:69C
19GF Score
Tvardi Therapeutics Inc FRA:69C
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tvardi Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tvardi Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=26.999+-9.292
=17.71

Tvardi Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=17.935+-0.764
=17.17

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €17.17 Mil mean?
Tvardi Therapeutics (FRA:69C) has a Ending Cash Position of €17.17 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Ending Cash Position too high?
Tvardi Therapeutics' current Ending Cash Position is €17.17 Mil. Overall, Tvardi Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Ending Cash Position compare to CRVO and JSPR?
Tvardi Therapeutics' Ending Cash Position of €17.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Ending Cash Position is €17.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (FRA:69C) has a current Ending Cash Position of €17.17 Mil. The current Ending Cash Position is €17.17 Mil. Tvardi Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Tvardi Therapeutics (FRA:69C), the current Ending Cash Position is €17.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
19GF Score

Get the complete analysis for FRA:69C

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.20
Price